The observation that HELB-depleted BRCA1-deficient tumor cells were resistant to a PARP inhibitor is consistent with an auto-regulatory mechanism to limit end-resection dependent on HELB and its interaction with RPA [57]. The gene discussed is HELB; the disease is neoplasm.